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Summary  Following  the  development  of  stents,  then  drug-eluting  stents  (DES),  bioresorbable
scaffolds  are  proposed  as  a  third  evolution  in  coronary  angioplasty,  aiming  to  reduce  the  inci-
dence of  restenosis  and  stent  thrombosis  and  to  restore  vascular  physiology.  At  least  16  such
devices are  currently  under  development,  but  published  clinical  data  were  available  for  only
three of  them  in  September  2014.  The  ﬁrst  device  is  Abbott’s  BVS®,  a  poly-L-lactic  acid  (PLLA)-
based everolimus-eluting  device,  which  has  been  tested  in  a  registry  and  two  non-randomized
trials. Clinical  results  seem  close  to  what  is  expected  from  a  modern  DES,  but  possibly  with
more post-procedural  side-effects.  Two  randomized  trials  versus  DES  are  underway.  This  device
is already  marketed  in  many  European  countries.  The  second  device  is  Elixir’s  DESolve®,  a  PLLA-
based novolimus-eluting  device,  which  has  been  evaluated  in  two  single-arm  trials.  Results
are not  widely  different  from  those  expected  from  a  DES.  The  third  device  is  Biotronik’s
®DREAMS ,  a  metallic  magnesium-based  paclitaxel-eluting  device,  which  has  been  assessed  in  an
encouraging  single-arm  trial;  its  second  version  is  currently  undergoing  evaluation  in  a  single-
arm trial.  The  available  results  suggest  that  the  technological  and  clinical  development  of
bioresorbable  scaffolds  is  not  yet  complete:  their  possible  clinical  beneﬁts  are  still  unclear
compared  with  third-generation  DES;  the  impact  of  arterial  physiology  restoration  has  to  be
Abbreviations: BMS, bare-metal stent; BVS, Bioresorbable Vascular Scaffold; DES, drug-eluting stent; DREAMS, Drug Eluting Absorbable
Metal Scaffold; MACE, major adverse cardiac events; OCT, optical coherence tomography; PLLA, poly-L-lactic acid; SBO, side-branch
occlusion STEMI, ST-segment elevation myocardial infarction.
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assessed  over  the  long  term;  and  their  cost-effectiveness  has  to  be  established.  From  the
perspective  of  a  health  technology  assessment,  there  is  no  compelling  reason  to  hasten  the
clinical use  of  these  devices  before  the  results  of  ongoing  randomized  controlled  trials  become
available.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Après  le  développement  des  stents,  puis  des  stents  actifs,  les  stents  actifs  entière-
ment résorbables  constituent  la  troisième  évolution  de  l’angioplastie  coronaire.  Ces  dispositifs
visent à  réduire  l’incidence  des  resténoses  et  des  thromboses  et  à  restaurer  la  physiologie
vasculaire.  Au  moins  seize  dispositifs  sont  en  développement  mais  seulement  trois  ont  fait
l’objet de  publications  jusqu’en  septembre  2014.  Le  premier  (ABBOTT—BVS®)  est  en  polymère
d’acide L-lactique  (PLLA)  délivrant  de  l’évérolimus.  Il  a  été  évalué  par  un  registre  et  deux
essais non  comparatifs.  Les  résultats  cliniques  semblent  proches  de  ceux  d’un  stent  actif  mais
avec peut-être  plus  d’événements  indésirables.  Deux  essais  comparatifs  randomisés  versus
stents actifs  sont  en  cours.  Ce  stent  est  commercialisé  dans  la  plupart  des  pays  européens.
Le deuxième  (Elixir—DESolve®),  (PLLA,  novolimus),  a  été  étudié  par  deux  suivis  de  cohorte.
Les résultats  ne  semblent  pas  différents  de  ceux  obtenus  avec  les  stents  actifs.  Le  troisième
(Biotronik—DREAMS®),  (alliage  magnésium-terres  rares,  paclitaxel),  a  fait  l’objet  d’un  suivi  de
cohorte encourageant  ;  l’industriel  étudie  une  deuxième  version  dans  le  cadre  d’une  cohorte.
Les résultats  disponibles  suggèrent  que  le  développement  technique  et  clinique  des  stents  actifs
entièrement  résorbables  n’est  pas  ﬁnalisé.  Les  bénéﬁces  cliniques  semblent  comparables  à  ceux
des stents  actifs  de  dernière  génération  et  ceux  imputables  à  la  récupération  de  la  vasomotri-
cité artérielle  ne  sont  pas  encore  démontrés  à  long  terme.  Leur  rapport  coût-efﬁcacité  n’est
pas encore  connu.  En  termes  d’évaluation  des  technologies  de  santé,  il  n’existe  pas  d’argument
convainquant  pour  en  recommander  l’utilisation  en  pratique  clinique  avant  le  résultat  des
études contrôlées  en  cours.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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estenosis  is  an  important  limitation  of  myocardial  revas-
ularization  after  routine  balloon  coronary  angioplasty
1,2].  An  ‘elastic  recoil’  phenomenon  was  mainly  involved
n  the  mechanism  of  restenosis  (along  with  constrictive
emodelling  and  neointimal  proliferation),  leading  to  the
evelopment  of  bare-metal  stents  (BMS)  [3].
While  the  widespread  use  of  BMS  enabled  a  reduction  in
arly  restenosis  and  in  the  incidence  of  arterial  wall  dis-
ection,  an  increase  in  the  incidence  of  late  restenosis  was
oted  and  attributed  primarily  to  neointimal  proliferation.
hese  observations  led  to  the  development  of  drug-eluting
tents  (DES)  [4],  whose  diffusion  of  antiproliferative  agents
as  accompanied  by  a  reduction  in  post-stenting  reinter-
ention  rates  [5,6].  However,  their  impact  on  clinical  events
ccurring  after  revascularization  remains  poorly  evaluated.
The  attention  of  interventional  cardiologists  has  now
urned  to  very  late  restenosis  and  thrombosis.  These  events
ay  be  induced  by  a  long-term  effect  of  the  polymer  bonding
he  stent  itself  to  the  drug  to  be  delivered  into  the  arterial
all.  The  ﬁrst  proposed  solution  to  this  issue  involved  biore-
orbable  polymer  stents  (the  metal  frame  of  which  stays
n  the  artery),  which  remain  in  development  [7,8].  More-
ver,  persistent  late  acquired  malapposition  with  durable
etal  stents  may  be  associated  with  chronic  inﬂammation,
‘
c
peoatherosclerosis,  very  late  lumen  loss  and  stent  throm-
osis  [9],  contrasting  with  the  fact  that  a stent  has  no
echanical  function  after  a  few  months.  It  has  also  been
rgued  that  the  presence  of  the  stent  suppresses  arterial
all  motility  and  vasodilation  ability.  This  line  of  rea-
oning  has  led  some  manufacturers  to  start  developing
ully  bioresorbable  devices  (usually  called  ‘scaffolds’  rather
han  ‘stents’)  for  coronary  artery  stenting.  Some  feasibil-
ty  studies  are  available,  but  large-scale  trials  are  yet  to  be
ublished.
The  present  paper  reviews  the  available  evidence  on  fully
ioresorbable  coronary  scaffolds,  with  a  heath  technology
ssessment  perspective,  setting  aside  the  development  of
esorbable  polymer  stents.
ethods
he  Comité  d’Évaluation  et  de  Diffusion  des  Innovations
echnologiques  (CEDIT)  undertook  an  early  assessment
f  this  emerging  health  technology  for  the  Assistance
ublique—Hôpitaux  de  Paris  (AP—HP).  A  systematic  search
or  relevant  literature,  using  subsets  of  the  set  (‘coronary’,
scaffold’,  ‘resorbable’  ‘stent’),  up  to  September  2014,  was
onducted  using  the  MEDLINE  and  EMBASE  databases,  com-
leted  by  a  manual  search  of  the  references  of  retrieved
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Figure 1. Fully bioresorbable scaffolds with published human
assessment. From top to bottom: Abbott’s BVS (version 1.1); Elixir’s
DESolve; Biotronik’s DREAMS (ﬁrst generation). Images courtesy of
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Absorbable  Metal  Scaffold  (DREAMS®) [17],  after  a  ﬁrst  iter-the respective manufacturers.
papers.  References  pertaining  to  ‘resorbable  polymer
stents’  only  were  rejected.
This  search  aimed  for  the  exhaustive  retrieval  of  formally
published  clinical  and  economic  results  relating  to  fully
bioresorbable  scaffolds  currently  on  the  market  or  under
development  in  humans,  while  giving  enough  technical  and
organizational  information  to  allow  for  decision  making  at
a  hospital  management  level.  We  limited  our  review  to
devices  for  which  we  retrieved  at  least  one  formally  pub-
lished  human  clinical  use  and  that  are  still  available  or  under
further  development.
As  is  customary  for  CEDIT  assessment  reports,  the
information  was  organized  under  four  headings:  techni-
cal,  clinical,  economic  and  organizational.  The  scarcity  of
available  information  precluded  formal  aggregation  (meta-
analysis)  of  the  results  and  led  us  to  quote  some  indirect
information,  such  as  press  releases.
Results
The  available  background  papers  [10—12]  summarize  a large
quantity  of  information  on  the  current  development  of  these
devices.  According  to  these  papers,  various  manufactur-
ers  have  started  the  development  of  at  least  16  different
devices  to  date.
Technical aspects
The  technical  characteristics  of  fully  resorbable  scaffolds
with  published  human  use  and  currently  under  develop-
ment  are  listed  in  Table  1;  these  devices  are  pictured  in
Fig.  1.
A  fully  bioresorbable  device  for  coronary  artery  stenting
was  attempted  early  in  the  1990s  [13];  however,  the  initial
success  of  DES  targeting  the  same  clinical  problem  caused
these  initial  efforts  to  be  discarded.
a
i
p387
All  currently  developed  fully  bioresorbable  scaffolds  but
ne  are  drug-eluting  devices;  therefore,  current  research
oncerning  the  associated  drugs  (sirolimus  or  paclitaxel
amilies)  is  relevant  to  these  devices.  In  contrast,  their
echanical  properties  strongly  depend  on  their  base  mate-
ial  and  are,  by  deﬁnition,  unstable,  as  the  device  is  bound
o  disappear  eventually.  The  question  to  be  answered  is
hether  the  mechanical  function  of  a  scaffold  is  sufﬁcient
or  its  clinical  purposes,  in  terms  of  strength  of  the  acute
tent  recoil  and  duration.
The  devices  for  which  we  retrieved  results  regarding
uman  clinical  use  are  based  on  two  classes  of  biomaterials:
oly-L-latic  acid  (PLLA)  polymers  and  magnesium  rare-earth
lloys.
LLA polymers
t  least  four  manufacturers  have  attempted  to  create  a
ioresorbable  scaffold  based  on  this  material.
In  2000,  Kyoto  Medical  Planning  (Kyoto,  Japan)  published
he  results  of  the  ﬁrst  clinical  trial  [13]  assessing  their  Igaki-
amai® biodegradable  coronary  stent.  This  ﬁrst-generation
evice  was  thermoplastic,  its  deployment  needing  the  injec-
ion  of  contrast  medium  heated  to  80 ◦C;  furthermore,  this
eployment  used  a  large-calibre  guide.  These  drawbacks
nd  the  initial  results  did  not  lead  the  manufacturer  to
ndertake  further  development  at  the  time  of  the  publi-
ation  of  the  ﬁrst  DES  clinical  results.  One  should  note,
owever,  the  recent  publication  of  the  10-year  follow-up  of
his  cohort  [11].  A  second  iteration  of  this  device  is  said  to
e  in  development.
Abbott  (Chicago,  IL,  USA)  has  also  developed  a  PLLA
evice  (the  ABSORB  Bioresorbable  Vascular  Scaffold  [BVS®]).
his  device  is  the  oldest  of  those  presently  aimed  at  the
arket  and,  therefore,  the  best  documented.  Some  infor-
ation  is  available  about  its  pharmacological  and  resorption
ynamics  [8]:  the  everolimus  elution  is  maximal  during  the
rst  weeks  and  null  after  3  months;  the  scaffold  provides
echanical  support  for  3  months,  but  its  strength  is  then
ost  rapidly;  the  structure  is  lost  6  months  after  implanta-
ion,  but  scaffold  elements  are  visible  up  to  2  years  after
mplantation.
The  manufacturer  Elixir  (Sunnyvale,  CA,  USA)  has  under-
aken  a  cohort  study  of  the  DESolve® bioresorbable  coronary
caffold  system  (16  patients);  a  larger  single-arm  trial  (DES-
lve  Nx)  has  been  completed  [14],  but  the  ﬁrst  results,
resented  orally  at  EuroPCR  2013  [15], have  not  yet  been
ublished.
The  French  start-up  company  Arterial  Remodeling  Tech-
ologies  (Noisy  le  Roi,  France)  has  undertaken  a  ﬁrst  cohort
tudy  (ARTDIVA,  30  patients,  ﬁve  centres)  assessing  a  PLLA-
ased  non-drug-eluting  resorbable  scaffold;  the  ﬁrst  30-day
ollow-up  results  were  presented  at  TCT  2013  [16],  but  await
ormal  publication.
agnesium rare-earth alloys
he  manufacturer  Biotronik  (Berlin,  Germany)  has  under-
aken  trials  evaluating  such  a  device,  called  the  Drug  Elutingtion  produced  disappointing  clinical  results  [18]. Detailed
nformation  about  the  mechanical  and  the  pharmacological
roperties  of  this  paclitaxel-eluting  device  does  not  seem
388  E.  Charpentier  et  al.
Table  1  Technical  characteristics  of  available  resorbable  coronary  scaffolds  with  published  human  use.
BVS  1.1  DESolve  1.0  DREAMS  1G
Manufacturer  Abbott  Elixir  Biotronik
Availability  CE  marked  CE  marked
Material  PLLA  PLLA  Magnesium
rare-earth
alloy
Eluted  drug Everolimus  Novolimus  Paclitaxela
Design  In-phase  hoops
with  straight
links
In-phase  hoops
with  straight
links
6-Crown
Strut  thickness  (m)  156  150  125
Radial  support  duration  6  months  —  3—6  months
Time  to  resorption  2—3  years  2—3  years  1  year
BVS: Bioresorbable Vascular Scaffold; CE: Conformité Européenne; DREAMS, Drug Eluting Absorbable Metal Scaffold; PLLA, poly-L-lactic
acid.
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o  have  been  published;  according  to  Patel  and  Banning  [9],
he  mechanical  strength  of  the  metallic  alloy  would  allow
or  less  beam  section  inﬂation  (150%)  than  for  a  PLLA-based
evice  (240%),  to  achieve  the  same  strength  as  a  chrome-
obalt  device.
ther devices
ther  manufacturers  have  announced  their  intention  to
ork  on  similar  devices.  Among  them  are  Reva  Medical  (San
iego,  CA,  USA)  (tyrosine  polycarboxylate-based  device),
hose  ﬁrst  clinical  trial  (RESTORE)  results  were  presented
t  TCT  2012;  a  second  pivotal  trial  (RESTORE  II)  has  been
nitiated  [12].  A  ﬁrst  iteration  of  the  IDEAL  (modiﬁed  PLLA-
ased)  device  led  to  disappointing  clinical  results;  a  second
teration  was  in  the  preclinical  evaluation  stage  in  2013.
ther  devices  have  not  yet  reached  the  stage  of  human
valuation  [12].
linical results
he  main  inclusion  criteria  of  the  published  trials  are  listed
n  Table  2,  the  patient  characteristics  are  described  in
able  3  and  the  lesion  characteristics  in  Table  4.  Pub-
ished  clinical  and  angiographical  results  are  summarized  in
able  5.
bbott’s BVS®
BSORB  cohort  studies
he  ﬁrst  iteration  of  this  device  was  evaluated  in  a  single-
rm  cohort  study  (ABSORB  A),  which  enrolled  30  patients
19]  (Table  2).  The  protocol  mandated  a  minimum  6-month
uration  of  dual  antiplatelet  therapy,  but  15  patients  were
till  receiving  this  at  1  year.  One  non-Q-wave  myocardial
nfarction  was  reported  during  the  ﬁrst  6  months  of  follow-
p;  this  event  was  the  only  cardiac  event  reported  over
 years  of  follow-up  (two  non-cardiac  deaths  were  reported,
ttributed  to  duodenal  ulcer  and  Hodgkin’s  disease).  The
uthors  also  reported  evidence  of  arterial  motility  at  2  years.
t
f
tncomplete  strut  apposition  at  baseline  was  reported  in  six
atients  (24%)  and  persisted  in  four  patients  at  180  days.
A  new  iteration  of  the  BVS  (version  1.1)  was  created,  aim-
ng  at  lowering  late  lumen  loss.  This  device  was  assessed  in
he  ABSORB  B  single-arm  cohort  study  [20—22].  This  cohort
f  101  patients  (102  lesions)  was  further  split  into  cohort  B1,
hose  members  had  invasive  coronary  imaging  (quantita-
ive  coronary  angiography,  intravascular  ultrasound  imaging
nd  optical  coherence  tomography  [OCT]  at  6  months  and
 years),  and  cohort  B2,  whose  members  had  the  same  exam-
nations  at  1  and  3  years;  all  patients  underwent  computed
omographic  angiography  at  1  year.  At  2  years,  nine  major
ardiovascular  events  had  been  reported  (three  non-Q-
ave  myocardial  infarctions  and  six  ischaemia-driven  target
esion  revascularizations).  An  initial  late  lumen  loss  was
bserved  in  cohort  B1  (going  from  6.53  mm2 immediately
fter  stenting  to  6.36  mm2 at  6  months),  followed  by  a  late
umen  gain  (6.85  mm2,  i.e.  +7.7%)  at  2  years,  with  similar
esults  using  other  imaging  modalities;  cohort  B2  gave  sim-
lar  results  (a  detailed  analysis  showed  no  change  in  the
caffold  area,  whereas  the  lumen  area  decreased  by  23.4%).
rterial  motility  was  observed  at  1  year  and  deemed  aug-
ented  at  2  years.
BSORB  EXTEND  international  continuing  accrual
tudy (registry)
artial  results  from  the  ABSORB  EXTEND  registry  are  avail-
ble.  An  aggregation  of  the  subgroups  of  patients  in  ABSORB
,  ABSORB  B  and  ABSORB  EXTEND  treated  in  Rotterdam
23]  concluded  on  the  efﬁcacy  and  safety  of  the  BVS  at
 month  post  procedure.  A  paper  on  the  results  obtained
or  the  450  ﬁrst  patients  [24]  reported  (without  details)
schaemia-driven  major  adverse  cardiac  events  (MACE)  in
.2%  of  patients  and  target  vessel  failure  in  4.7%  of  patients;
t  also  discussed  in  detail  three  device  dislodgements  and
our  cases  of  late  device  thrombosis.More  importantly,  a  retrospective  study  [25]  compared
he  rate  of  side-branch  occlusion  (SBO)  in  435  patients
rom  the  ABSORB  EXTEND  registry  and  250  patients  from
he  Xience® (ABBOTT’s  everolimus-eluting  stent)  arm  of  the
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Table  2 Main  inclusion  and  exclusion  criteria  of  published  studies.
Study  Age
(years)
Number  of  lesions Artery  Length
(mm)
Diameter
(mm)
TIMI Stenosis
(%)
AMI  LVEF  (%) Diffa Other
ABSORB  A >  18 One  de  novo Native  ≤  8 3 >  1 50  ≤  s  <  100 No  >  30 No
ABSORB  B >  18 One  or  two  de
novo  (different
vessels)
Native  ≤  4 ≤ 3 > 1 50  <  s  <  100 No  >  30 No
ABSORB
Extend
>  18 One  or  two  de
novo  (different
vessels)
Native  ≤  28 2 ≤  d  ≤  3.8 ≥ 1 < 100 No  —  No  In-stent
restenosis  or
thrombus
ABSORB  II 18  <  a  ≤  85 One  or  two  de
novo  (different
vessels)
—  ≤  48 2.25  ≤  d  ≤  3.8 ≥  1 50  <  s  <  100 No  >  30 No  No  recent  PCI,
bypass  lesion
Prague  19 —  —  —  ≤  24  2.3  ≤  d  ≤  3.7  —  —  Yesb —  —  In-stent
restenosis  or
thrombus
BVS  STEMI 18  <  a  ≤  85 —  —  —  2.0  ≤  d  ≤  3.8  —  —  Yesb —  —  Previous  CABG,
thrombus  in  stent
DESolve
First-in-
Man
—  One  or  two  de
novo
Native  ≤  10 ≤ 10 —  ≤  80 No  >  30  —  Recent
myocardial
infarction,
restenosis,
calciﬁcations
BIOSOLVE-1 —  One  or  two  de
novo  (different
vessels)
—  ≤  12 3.0  ≤  d  ≤  3.5 —  50  ≤  s  ≤  99 No  —  No
a: age; AMI: acute myocardial infarction; BVS: Bioresorbable Vascular Scaffold; CABG: coronary artery bypass graft; d: diameter; Diff: difﬁcult lesion (e.g. calciﬁed, ostial or furcation
lesions, angulations, thrombus); LVEF: left ventricular ejection fraction; s: stenosis; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; TIMI:
thrombolysis in myocardial infarction.
a Most studies excluded difﬁcult lesions (calciﬁed, ostial or furcation lesions, angulations, thrombus).
b Inclusion criterion.
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Table  3  Compilation  of  the  characteristics  of  patients  treated  with  resorbable  devices  in  published  studies.
Study  ABSORB  A
(n  =  30)
ASBORB  B
Small  vesselsa
(n  =  41)
ABSORB  B
Large  vessels
(n  =  60)
ABSORB  Extend
(ﬁrst  512
patients)  (n  =  512)
Prague  19
(n  =  40)
BVS  STEMI
(n  =  49)
ABSORB  II
(BVS  group)
(n  =  335)
DESolve
First-in-Man
(n  =  16)
BIOSOLVE-
1
(n  =  46)
Age  (years)  62  ±  9  62.4  ±  9.4  62.2  ±  8.7  62  ±  11  58.9  ±  10.9  58.9  ±  10.5  61.5  ±  10.0  69.3  ±  8.4  65.3  ±  9.7
Male  sex  18  (60)  26  (63)  47  (78)  74%  31  (78)  38  (78)  253  (76)  10  (63)  34  (74)
Smokerb 6  (20)  9  (22)  8  (14)  23%  25  (62)  27  (69)  79  (24)  11  (69)  17  (37)
Diabetesb 1  (3)  9  (22)  8  (13)  26%  1  (3)  4  (8)  80  (24)  1  (6)  7  (15)
Hypertensionb 18  (60)  24  (58)  38  (64)  65%  —  19  (39)  231  (69)  10  (63)  40  (87)
Hyperlipidaemiab 19  (63)  35  (85)  44  (73)  67%  —  11  (22)  252  (75)  11  (69)  41  (89)
Previous
target
vessel
intervention
3  (10)  —  —  5%  —  —  14/120  (12)  —  —
Previous  PCTA  —  6  (15)  15  (25)  —  1  (3)  0  (0)  —  —  27  (59)
Previous  CABG  —  1  (2)  2  (3)  —  0  0  —  —
Previous
myocardial
infarction
1  (3)  7  (18)  18  (30)  16%  1  (3)  1  (2)  93  (28)  4  (25)  15  (33)
Functional
status
Silent
ischaemia
1  (3)  —  —  5%  0  —  42  (13)  5  (31)  1  (2)
Stable
angina
21  (70)  —  —  64%  0  —  214  (64)  11  (69)  43  (93)
Unstable
angina
8  (27)  —  —  31%  0  —  68  (20)  0  2  (4)
Myocardial
infarction
0  0  0  0  40  (100)  —  0  0  0
Data are expressed as mean ± standard deviation or number (%, unless otherwise indicated. BVS, Bioresorbable Vascular Scaffold; CABG: coronary artery bypass graft; PCTA: percutaneous
transluminal coronary angioplasty; STEMI: ST-segment elevation myocardial infarction.
a The ABSORB B study investigators present most of their results separately for small (diameter < 2.5 mm) and large target vessels.
b Deﬁnition (present/history) varies among studies.
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Table  4 Compilation  of  the  characteristics  of  lesions  treated  with  resorbable  devices  in  published  studies.
Study  ABSORB  A  ABSORB  B
Small  vesselsa
ABSORB  B
Large
vessels
ABSORB
Extend  (ﬁrst
512  patients)
Prague  19  BVS  STEMI  ABSORB  II
(BVS  group)
DESolve
First-in-Man
BIOSOLVE-1
Device  BVS  1.0 BVS  1.1 BVS  1.1 BVS  1.1 BVS  1.1 BVS  1.1 BVS  1.1 DESolve  DREAMS
Number  of  lesions 30  41  61  93%  single;
7%  double
40  49  364  16  47
Localization
Left  anterior
descending
14 (47) 19  (46) 25  (41) 45%  20  (50) 21  (43) 163  (45) 3  (21)b 16  (34)
Left  circumﬂex 9  (30) 8 (20) 15  (25) 26%  11  (28) 6  (12) 106  (29) 5  (38)b 16  (34)
Right  coronary
artery
7 (23) 13  (32) 21  (34) 29%  9  (23) 22  (45) 95  (26) 6  (43)b 15  (32)
LMCA/ramus  0  0  0  1%  0  0  0  0  0
Saphenous  graft 0  0  0  0  0  0  0  0  0
ACC/AHA  lesion
classiﬁcation
A 0  0  1  (2)  —  —  —  5  (1)  5  (38)b 12  (26)
B1  18  (60)  21  (53)  34  (57)  —  —  —  193  (53)  4  (29)b 31  (66)
B2  12  (40) 18  (45) 22  (37) 41%  —  —  159  (44) 5  (38)b 4  (9)
C  0  1  (3) 3  (5) —  —  6  (2) 0b  0
Preintervention
characteristics
—  —
Lesion  length  (mm) 9.15  ±  3.99 —  —  —  —  —  —  2.65  ±  0.32b 2.73  ±  0.48
Mean  reference
vessel  diameter
(mm)
2.72  ±  0.47 2.27  ±  0.15 2.83  ±  0.29 2.62  ±  0.35 —  2.63  ±  0.53 2.59  ±  0.38 0.81  ±  0.29b 1.21  ±  0.52
Minimum  luminal
diameter  (mm)
1.06  ±  0.26 0.97  ±  0.20 1.12  ±  0.30 1.08  ±  0.31 —  1.21  ±  0.46 1.07  ±  0.32 70%  ±  10.5%b 55.9  ±  16.7
Diameter  stenosis
(%)
60 ±  11 57.0  ±  9.3 60.3  ±  10.3 59  ±  10 —  53.2  ±  16.1 59  ±  11 8.95  ±  2.64b 10.99  ±  4.59
Data are expressed as mean ± standard deviation, number (%), unless otherwise indicated. ACC: American College of Cardiology; AHA: American Heart Association; BVS, Bioresorbable
Vascular Scaffold; LMCA: left main coronary artery; STEMI: ST-segment elevation myocardial infarction.
a The ABSORB B study investigators present most of their results separately for small (diameter < 2.5 mm) and large target vessels.
b Reported on a modiﬁed intention-to-treat population (see text and original paper).
392
 
E.
 Charpentier
 et
 al.
Table  5  Compilation  of  clinical  and  angiographical  follow-up  results  of  resorbable  scaffolds.
Study  Lesion
length
(mm)
Reference  vessel
diameter  (mm)
In-scaffold
minimal  diameter
(mm)
Diameter
stenosis
(%)
Procedural
success
MACE  Late
scaffold
thrombosis
In-scaffold
late  loss
(mm)
Stent  area
reduction
(%)
ABSORB  A  (BVS  1.0)  [34]
Preprocedure  9.15  ±  3.99  2.72  ±  0.47  0.06  ±  0.26  60  ±  11  —  —  —  —  —
Post-procedure  —  —  2.32  ±  0.31  16  ±  6  100  —  —  —  —
6  months  (30  pts)  [34]  —  —  —  —  —  3.3  0  0.44  ±  0.35  —11.8
1  year  (29  pts)  [34]  —  —  —  —  —  3.4  —  —  —
2  years  (29  pts)  [19]  —  —  —  —  —  3.4  0  0.48  ±  0.28  —27
3  years  (29  pts)  [35]  —  —  —  —  —  3.4  —  —  —
4  years(29  pts)  [36]  —  —  —  —  —  3.4  —  —  —
5  years  (29  pts)  [37]  —  —  —  —  —  3.4  0  —  —
ABSORB  Ba (BVS  1.1)
[21,38]
Preprocedure,  global  10.2  ±  3.9  2.65  ±  0.46  1.06  ±  0.32  60  ±  12  100  —  —  0.19  ±  0.18b —5.4b
Small  vessels
(<  2.5  mm)  (41  pts)
— 2.27  ±  0.15  2.83  ±  0.29  57  ±  9.3  —  —  —  —  —
Large  vessels
(≥  2.5  mm)  (60  pts)
—  0.97  ±  0.20  1.12  ±  0.30  60.3  ±  10.3  —  —  —  —  —
Post-procedure  —  —  —  —  —  —
Small  vessels
(<  2.5  mm)  (41  pts)
— —  2.17  ±  0.22  13.8  ±  4  —  —  —  —  —
Large  vessels
(≥  2.5  mm)  (60  pts)
—  —  2.37  ±  0.23  16.2  ±  6.7  —  —  —  —  —
Six  months  [21]  —  —  —
Small  vessels
(20  pts)
—  —  —  18.1  ±  7.2  —  3/41
(7.3)
0  0.16  ±  0.18b —18.1b
Large  vessels
(25  pts)
—  —  —  20.2  ±  8.0  —  2/60
(3.3)
0  0.21  ±  0.17b —20.2b
One  year  [20]  —  —  —  —
Small  vessels
(21  pts)
—  —  —  18.8  ±  10.5  —  3/41
(7.3)
0  0.27  ±  0.32c —
Large  vessels
(35  pts)
—  —  —  22.5  ±  11.5  —  4/60
(6.7)
0  0.27  ±  0.32c —
Two  years  [20]  —  —  —  —  —
Small  vessels
(20  pts)
—  —  —  20.72  ±  7.33  —  3/41
(7.3)
0  0.29  ±  0.16  —
Large  vessels
(25  pts)
—  —  —  21.17  ±  8.11  —  6/59
(10.2)
0  0.25  ±  0.22  —
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Table  5 (Continued)
Study  Lesion
length
(mm)
Reference  vessel
diameter  (mm)
In-scaffold
minimal  diameter
(mm)
Diameter
stenosis
(%)
Procedural
success
MACE  Late
scaffold
thrombosis
In-scaffold
late  loss
(mm)
Stent  area
reduction
(%)
Prague  19  (BVS  1.1)  [27]
1-year  clinical
follow-up
— —  —  —  —  2/40  (5) 1  (2.5) —  —
BVS  STEMI  (BVS  1.1)
[28]
1-month  results —  —  —  —  48/49
(97.9)
—  —  —  —
ABSORB  EXTEND
(BVS  1.1)  (ﬁrst
512  pts)  [26]
—  —  —  —  540/548
(98.5)
lesions
1/49
(2.6)
— —  —
1  month —  —  —  —  —  2.1  0.4  —  —
3  months —  —  —  —  —  2.9  0.6  —  —
1  year —  —  —  —  —  4.3  0.8  —  —
ABSORB  II  (BVS  1.1)  [30]
1-year  interim
analysis  of  BVS  group
(335  pts)
—  —  —  —  361/364
(99)
16/315
(5)
3/364  (0.9)  —  —
DESolve  First-in-Man
(16  pts)  [33]
—  —  —  —  15/15
(100)d
—  —  —  —
1  month  —  —  —  —  —  1  0  —  —
6  months  —  —  —  —  —  2  0  0.19  ±  0.19  —
1  year  —  —  —  —  —  3  0  —  —
BIOSOLVE-1  (DREAMS)
(46  pts)  [17]
—  —  —  —  47/47
(100)
—  —  —  —
1  month  —  —  —  —  —  0/46  0  —  —
6  months —  —  —  —  —  2/46
(4.3)
0  0.65  ±  0.50  —
1  year  —  —  —  —  —  3/43  (7)  0  0.52  ±  0.39  —
Data are expressed as mean ± standard deviation, number (%) or %. BVS, Bioresorbable Vascular Scaffold; MACE: major adverse cardiac events; pts: patients; STEMI: ST-segment elevation
myocardial infarction.
a The ABSORB B study investigators present most of their results separately for small (diameter < 2.5 mm) and large target vessels.
b 6-month imaging subcohort (45 pts).
c 1-year imaging subcohort (56 pts, 57 lesions).
d Reported on a modiﬁed intention-to-treat population.
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PIRIT  trial.  SBO  was  observed  in  73/1209  patients  in  the
BSORB  EXTEND  group  versus  28/682  in  the  SPIRIT  group
6%  vs  4.1%;  p  =  0.09);  these  SBOs  were  associated  with
n-hospital  non-Q-wave  myocardial  infarction  (6.5%  in  the
BO  group  vs  0.5%  in  the  non-SBO  group;  p  <  0.01).  Mul-
ivariable  analysis  conﬁrmed  the  association  of  BVS  with
ost-procedural  SBO  (Odds  Ratio  2.09,  95%  conﬁdence  inter-
al  1.18—3.68);  the  results  from  a  subgroup  analysis  suggest
hat  this  association  may  exist  only  for  a  side  branch  diam-
ter  <  0.5  mm  (p  =  0.08,  not  signiﬁcant).
Recently,  a  preliminary  report  of  the  12-month  clinical
utcomes  in  the  ﬁrst  512  patients  enrolled  [26]  found  that
t  1  year,  the  frequencies  of  the  composite  endpoints  of
schaemia-driven  MACE  and  ischaemia-driven  target  vessel
ailure  were  4.3%  and  4.9%,  respectively.  The  cumulative
ate  of  Academic  Research  Consortium-deﬁned  deﬁnite  and
robable  scaffold  thrombosis  for  this  population  was  0.8%  at
 year.
rague  19
 recent  paper  [27]  reported  the  systematic  use  of  Abbott’s
VS  1.1  for  the  management  of  eligible  patients  presenting
ith  acute  ST-segment  elevation  myocardial  infarction
STEMI)  during  a  7.5-month  period,  and  compared  their  out-
omes  with  those  of  ineligible  patients  during  the  same
eriod.  The  authors  reported  a  98%  procedural  success
ate,  95%  of  patients  regaining  arterial  patency  (Throm-
olysis  In  Myocardial  Infarction  3  ﬂow);  an  OCT  imaging
ubstudy  (21  patients)  showed  edge  dissection  in  38%  and
trut  malapposition  in  1.1%.  These  patients  had  clinical  out-
omes  similar  to  those  of  ineligible  patients  treated  with
MS  (event-free  survival  of  95%  in  patients  treated  with  the
VS  and  of  93%  in  patients  treated  with  BMS).  Leaving  aside
he  comparison  (which  compared  dissimilar  populations),
his  continuous  case  series  demonstrated  the  feasibility  and,
o  some  extent,  the  safety  of  the  BVS  in  the  setting  of  pri-
ary  angioplasty  for  patients  with  STEMI.
VS  STEMI
his  study  [28],  similar  to  Prague  19,  included  49  patients
mong  a  cohort  of  125  eligible  (mostly  in  terms  of  lesion
ize  and  patient  history)  patients  presenting  with  an  acute
TEMI;  the  criteria  for  treatment  allocation  were  not
eported.  The  authors  reported  no  occurrence  of  MACE  at
0-day  follow-up  and  satisfactory  angiographic  results.  Sim-
lar  to  Prague  19,  this  study  demonstrated  the  feasibility  of
VS  implantation  in  patients  presenting  with  acute  STEMI,
lthough  with  a  very  short  follow-up.
ngoing  and  forthcoming  studies
he  investigators  of  two  comparative  trials  have  announced
heir  protocols;  one  has  also  produced  some  intermediary
esults.
The  ABSORB  II  trial  (initiated  by  Abbott)  is  comparing
29]  the  BVS  (335  patients)  with  the  Xience  everolimus-
luting  metal  stent  (166  patients)  in  a  wider  population  (see
able  2  for  criteria).  Clinical  follow-up  is  planned  at  30  and
80  days  and  at  1,  2  and  3  years.  The  primary  endpoint  is
imed  at  demonstrating  the  superiority  of  the  BVS  versus
he  XIENCE  stent  in  terms  of  vasodilation  properties  of  the
reated  segment  at  2  years,  deﬁned  (using  quantitative  coro-
ary  angiography)  as  the  change  in  the  mean  lumen  diameter
efore  and  after  administration  of  nitrates,  along  with  the
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on-inferiority  (reﬂex  to  superiority)  of  the  minimum  lumen
iameter  at  2  years  (same  basis).  In  an  interim  1-year  anal-
sis  of  clinical  and  procedural  secondary  outcomes  [30], the
uthors  found  that  there  were  17  (5%)  MACE  in  the  biore-
orbable  scaffold  group  compared  with  ﬁve  (3%)  (p  =  0.35)
n  the  metallic  stent  group,  with  the  most  common  event
eing  myocardial  infarction  (15  cases  [4%]  vs  2  cases  [1%],
espectively).
The  aim  of  the  randomized  AIDA  trial  [31]  is  to  demon-
trate  the  non-inferiority  of  the  BVS  stent  (compared  with
wo  everolimus-eluting  stents  of  similar  design)  in  a  wide
ange  of  coronary  percutaneous  intervention  indications,
ntending  to  mimic  its  planned  use  in  ‘all  comers’  popu-
ation.  This  study  was  initiated  and  is  sponsored  by  the
cademic  Medical  Center,  University  of  Amsterdam,  and  is
urrently  enrolling  patients  [32].
lixir’s DESolve®
he  First-in-Man  trial  [33]  of  the  DESolve  myolimus-eluting
caffold  included  16  patients  with  evidence  of  myocardial
schaemia  due  to  a  single  de  novo  lesion  (see  Table  2  for
etails).
One  lesion  could  not  be  reached  within  the  protocol-
llotted  time  and  was  excluded  from  further  analysis;
mmediate  success  was  achieved  in  the  15  remaining
atients.  One  patient  presented  a  spiral  dissection  distal
o  the  stent;  a  non-Q-wave  myocardial  infarction  followed
he  repair  surgery.  Between  30  days  and  6  months,  one  tar-
et  lesion  revascularization  using  a  DES  was  reported  for
 proximal  left  circumﬂex  stenosis  (85.9%  diameter  steno-
is)  located  adjacent  to  the  widely  patent  scaffold.  Between
 months  and  12  months,  one  event  was  reported:  a  cardiac
eath  following  non-target  vessel  coronary  artery  bypass
rafting  and  aortic  valve  replacement.  There  were  no  other
ACE  directly  attributable  to  the  scaffold  nor  cases  of
caffold  thrombosis  as  adjudicated  by  the  clinical  events
ommittee  throughout  the  12-month  time  period.
Imaging  studies  at  6  months  showed  that  the  in-scaffold
ate  lumen  loss  was  0.19  ±  0.19  mm  (according  to  quan-
itative  coronary  angiography);  neointimal  volume  (by
ntravascular  ultrasound  imaging)  was  7.19  ±  3.56%,  with
o  evidence  of  scaffold  recoil  or  late  malapposition.  Find-
ngs  were  conﬁrmed  with  OCT  and  showed  uniform  thin
eointimal  coverage  (0.12  ±  0.04  mm).  At  12  months,  multi-
lice  computed  tomography  demonstrated  excellent  vessel
atency.
Elixir  has  completed  enrolment  in  a  second  single-arm
rial  (DESolve  NX)  [14];  the  6-month  results  have  been  pre-
ented  [15]  at  EuroPCR  2013,  but  no  information  about  this
rial  has  been  formally  published.
iotronik’s DREAMS®
valuation  of  the  efﬁcacy  and  safety  of  the  ﬁrst  iteration
f  this  device  was  the  aim  of  the  BIOSOLVE-I  single-arm
rial  [17], which  included  46  patients  presenting  with  sta-
le  or  unstable  angina  or  documented  silent  ischaemia,  with
wo  de  novo  lesions  at  most  (Table  2).  The  primary  out-
ome  was  the  occurrence  of  a  composite  endpoint  of  death,
arget  vessel  myocardial  infarction  or  clinically  driven  tar-
et  lesion  revascularization;  secondary  outcomes  were  late
umen  loss,  restenosis  (percentage  and  binary)  at  6  and
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12  months,  device  thrombosis  and  cumulative  target  lesion
failure  at  6,  12,  24  and  36  months.
Forty-six  patients  were  included  (47  lesions),  all  of
whom  were  successfully  treated.  Two  patients  withdrew
their  consent  to  follow-up  after  the  6-month  examination;
one  patient  died  of  a  non-cardiac  cause  at  day  210  (the
reported  cause  of  death  was  ‘haemolytic  anaemia,  which
was  probably  drug  induced’)—the  authors  did  not  discuss  the
possible  link  between  this  event  and  the  drugs  prescribed  by
study  protocol;  two  myocardial  infarctions  occurred  during
the  6-month  coronary  angiography  itself  (both  successfully
treated  with  a  DES);  a  third  patient  presented  a  lesion  in
a  side  branch  of  the  target  vessel.  The  authors  reported
a  late  lumen  loss  of  0.52  mm  and  a  statistically  signiﬁcant
stenosis  increase  at  6  months,  with  no  signiﬁcant  variation
between  6  months  and  1  year;  six  lesions  (seven  segments)
presented  a  binary  restenosis  at  6  months  and  two  more
lesions  (three  segments)  at  1  year.  OCT  imaging  undertaken
in  seven  patients  showed  some  malapposed  struts  in  three
patients.  The  authors  deemed  these  results  to  be  similar  to
DES  or  Abbott’s  BVS  in  terms  of  target  lesion  failure;  how-
ever,  they  deemed  their  late  lumen  loss  results  to  be  inferior
to  those  of  these  comparators  and  concluded  that  another
device  iteration  was  required.
The  BIOSOLVE-II  trial,  evaluating  the  second-generation
DREAMS,  is  currently  recruiting  patients  [32].
Economic aspects
Currently,  the  only  Conformité  Européenne-marked
resorbable  scaffolds  are  Abbott’s  BVS  and  Elixir’s  DESolve.
The  BVS  is  currently  marketed  in  many  European  countries,
including  France,  where  the  regulatory  authorities  do  not
oppose  the  use  of  this  device,  but  so  far  have  not  taken
the  decision  to  reimburse  it.  Furthermore,  the  regulatory
authorities  require  that  centres  using  the  device  register
all  patients  in  the  FRANCE-ABSORB  registry,  undertaken  in
collaboration  with  the  French  Society  of  Cardiology.
To  the  best  of  our  knowledge,  no  economic  evaluation
study  is  currently  available.  Because  the  current  price  of
the  device  is  said  to  be  about  D  1050,  more  than  D  200
higher  than  the  reimbursed  price  of  a  third-generation  DES,
the  existence  of  this  certain  overcost  and  of  a  yet  unde-
termined  relative  beneﬁt  make  likely  a  high  incremental
cost-effectiveness  ratio  over  third-generation  DES.
Regulatory and ethical aspects
According  to  our  information,  these  devices  do  not  seem  to
present  any  speciﬁcities  that  differ  from  existing  DES;  there-
fore,  their  regulatory  issues  should  not  differ  from  those  of
DES.  The  available  results  do  not  seem  to  raise  any  speciﬁc
ethical  or  organizational  concerns.
Discussion
The  availability  of  a  fully  bioresorbable  coronary  scaffold
is  conceptually  very  attractive  for  the  interventional  cardi-
ologist,  offering  potential  advantages  over  third-generation
DES:  preservation  of  vessel  geometry,  restoration  of  physi-
ological  vasomotion,  late  positive  remodelling  and  eventual
s
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isappearance  of  any  foreign  material  into  the  arterial  wall
n  long-term  follow-up.  Have  we  reached  the  ‘ideal’  stent?
ertainly  not,  because  the  history  of  these  new  devices
howed  that  their  engineering  and  technological  devel-
pment  raised  many  issues,  from  bench  to  experimental
valuation  in  animals  and  ﬁnally  to  clinical  studies  in  man.
he  available  materials  that  are  susceptible  to  resorption
ave  mechanical  characteristics  weaker  than  those  of  the
hrome-cobalt  alloys  used  for  BMS.  A  mechanical  strength
ufﬁcient  for  the  stent’s  expected  function  requires  the
anufacturing  of  a  bulkier  device  (other  design  characteris-
ics  being  equal).  This  problem  hampered  the  development
f  the  ﬁrst  scaffold  (Igaki-Tamai)  and  might  contribute  to
he  excess  of  SBO  reported  for  the  BVS  stent.  However,  the
ates  of  restenosis  were  similar  between  the  BVS  and  the
verolimus-eluting  stents  suggesting  that  the  radial  force
f  the  BVS  is  able,  for  a  certain  amount  of  time,  to  limit
he  elastic  recoil  and  constrictive  remodelling  as  well  as  the
ate-generation  DES.  In  this  respect,  the  magnesium  rare-
arth  alloy  used  in  the  DREAMS  device,  which  has  better
echanical  strength,  might  be  of  interest;  however,  the  ﬁrst
teration  of  this  device  had  other  problems.
Issues  with  strut  fracture  due  to  the  inability  of  the
olymeric  device  to  achieve  full  expansion  require  some
recaution  with  stent  implantation.  Predilatation  is  manda-
ory;  primary  stenting  is  not  allowed  with  the  BVS.
ver-stretching  is  recommended  quite  routinely  to  avoid
alapposition,  but  no  more  than  0.25  mm  over  the  initial
iameter  of  the  stent.  Thus,  this  over-stretching  must  be
one  very  carefully  with  non-compliant  balloons.  Stent  dis-
uption  may  also  have  some  serious  secondary  effects,  such
s  coronary  rupture.
A  second  problem  is  the  dynamics  of  stent  resorption.  Too
ast  a resorption  may  have  contributed  to  disputable  results,
eading  to  various  device  design  iterations  (BVS  and  DREAMS,
mong  others).  Resorption  dynamics  also  have  to  be  con-
istent  with  the  dynamics  of  drug  elution  in  drug-eluting
evices.
Technological  development  is  also  needed  if  we  want
he  widespread  use  of  bioresorbable  scaffolds  in  our  daily
ngioplasty  practice.  Deliverability,  pushability  and  cross-
ng  proﬁle  need  to  be  improved  in  order  to  evaluate  the
fﬁcacy  of  BVS  in  tortuous,  calciﬁed,  ostial  or  bifurcation
esions,  small  vessels  and  also  chronic  total  occlusion.  In
ost  randomized  trials,  patients  with  complex  lesions  such
s  these  were  excluded.  The  kissing  technique,  used  and
ecommended  in  the  treatment  of  bifurcation  lesions,  is  not
ecommended  with  the  BVS.
We  have  only  limited  data  regarding  some  ‘ideal’  clinical
ituations  for  bioresorbable  scaffolds,  such  as  acute  coro-
ary  syndromes.  Even  if  we  consider  that  the  thicker  struts
nd  larger  wall  surface  coverage  with  the  BVS  might  entrap
ore  thrombotic  material,  limiting  distal  embolization  and,
ventually,  the  no-reﬂow  phenomenon,  there  was  no  clear
linical  beneﬁt  [27].  Primary  stenting  without  predilatation,
ontributing  to  some  positive  effects  on  the  limitation  of
istal  embolization,  is  not  authorized  with  bioresorbable
caffolds.  So,  in  this  setting,  even  if  the  BVS  may  be  used
afely  and  effectively,  one  cannot  recommend  using  it  in
ll-comers  with  acute  coronary  syndromes.
Late  resorption  of  the  scaffold  (up  to  2—3  years)  raises
he  issue  of  the  optimal  duration  of  dual  antiplatelet
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herapy,  which  is  recommended  for  a  minimal  duration  of
 months  after  DES  implantation  in  European  guidelines.  We
ave  no  evidence  that  this  duration  could  be  shortened  and
ventually  reduce  the  risk  of  haemorrhagic  complications
ithout  increasing  the  risk  of  in-stent  thrombosis.  Further
tudies  dedicated  to  this  speciﬁc  issue  are  warranted  and
egistries  will  be  valuable  for  determining  the  rate  of  late
tent  thrombosis  with  bioresorbable  scaffolds.  Eventually,
ll  manufacturers  argue  about  the  clinical  value  of  restor-
ng  the  vessel  geometry  and  vasomotricity  on  long-term
ollow-up.  Long-term  clinical  beneﬁt  (5—10  years)  needs  to
e  determined  in  large  registries  if  we  want  to  demon-
trate  any  signiﬁcant  clinical  differences  (mainly  on  hard
linical  endpoints,  such  as  myocardial  infarction  and  death)
egarding  the  low  rate  of  MACE.
From  an  economic  point  of  view,  any  signiﬁcant  cost
xcess  for  the  scaffolds  over  current  DES  will  translate  into
n  incremental  cost-effectiveness  ratio  that  is  quite  pos-
ibly  unfavourable.  Further  development  of  these  devices
ppears  therefore  as  a  wager  to  the  manufacturers  and  their
nvestors.
Given  the  current  state  of  our  information,  there  do
ot  seem  to  be  clinical  reasons  to  choose  one  of  these
evices  over  current  third-generation  DES;  further  research
s  necessary—and  possibly  further  development.  The  large-
cale  comparative  randomized  trials  undertaken  with  the
VS  device  might  give  a  better  understanding  of  the  possi-
le  late  (and  very  late)  clinical  beneﬁts  of  these  innovative
nd  attractive  devices.  Furthermore,  the  value  of  the  design
f  the  AIDA  trial,  which  explicitly  aims  to  assess  results  in
everyday’  use,  should  be  underscored.
onclusion
linical  results  published  up  to  September  2014  are  insuf-
cient  to  allow  a  judgment  to  be  made  about  the  clinical
erformance  of  bioresorbable  drug-eluting  coronary  scaf-
olds.  However,  a  ‘ﬁrst  impression’  of  clinical  behaviour  is
lose  to  that  obtained  after  the  ﬁrst  results  with  DES.  Any
linical  beneﬁt  of  scaffolds  over  DES  remains  to  be  demon-
trated,  and  the  initial  results  do  not  lead  to  the  expectation
f  large  superiorities.  Given  the  design  of  the  bioresorbable
caffolds,  potential  clinical  beneﬁt  might  be  expected  in
erms  of  late  or  very  late  outcomes.  At  this  stage,  one  can
ay  that  the  BVS  is  similar  to  the  everolimus-eluting  coronary
tent  in  terms  of  safety  and  efﬁcacy  in  selected  patients  with
on-complex  lesions.
isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
eferences[1] Cowley MJ, Vetrovec GW, Wolfgang TC. Efﬁcacy of percuta-
neous transluminal coronary angioplasty: technique, patient
selection, salutary results, limitations and complications. Am
Heart J 1981;101:272—80.
[E.  Charpentier  et  al.
[2] Gruentzig AR, King 3rd SB, Schlumpf M, Siegenthaler W.
Long-term follow-up after percutaneous transluminal coro-
nary angioplasty. The early Zurich experience. N Engl J Med
1987;316:1127—32.
[3] Roubin GS, King 3rd SB, Douglas Jr JS, Lembo NJ, Robinson
KA. Intracoronary stenting during percutaneous transluminal
coronary angioplasty. Circulation 1990;81:IV92—100.
[4] Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultra-
sound ﬁndings in the multicenter, randomized, double-blind
RAVEL (RAndomized study with the sirolimus-eluting VEloc-
ity balloon-expandable stent in the treatment of patients
with de novo native coronary artery Lesions) trial. Circulation
2002;106:798—803.
[5] Capodanno D, Dipasqua F, Tamburino C. Novel drug-eluting
stents in the treatment of de novo coronary lesions. Vasc Health
Risk Manag 2011;7:103—18.
[6] Tamburino C, Capodanno D. Evolution of stents: past, present
and future. Expert Rev Cardiovasc Ther 2009;7:443—6.
[7] Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting
biodegradable polymer-coated stent versus durable polymer-
coated sirolimus-eluting stent in unselected patients receiving
percutaneous coronary intervention (SORT OUT V): a ran-
domised non-inferiority trial. Lancet 2013;381:661—9.
[8] Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll
Cardiol 2010;56:S43—78.
[9] Patel N, Banning AP. Bioabsorbable scaffolds for the treatment
of obstructive coronary artery disease: the next revolution in
coronary intervention? Heart 2013;99:1236—43.
10] Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P.
Bioresorbable scaffolds: rationale, current status, challenges,
and future. Eur Heart J 2014;35:765—76.
11] Nishio S, Kosuga K, Igaki K, et al. Long-Term (> 10 years)
clinical outcomes of ﬁrst-in-human biodegradable poly-l-
lactic acid coronary stents: Igaki-Tamai stents. Circulation
2012;125:2343—53.
12] Zhang Y, Bourantas CV, Farooq V, et al. Bioresorbable scaf-
folds in the treatment of coronary artery disease. Med Devices
2013;6:37—48.
13] Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of
biodegradable poly-l-lactic acid coronary stents in humans.
Circulation 2000;102:399—404.
14] Reuters. Elixir medical announces enrollment completion of
the DESolve Nx Pivotal Trial for fully bioresorbable coronary
scaffold system; 2012 [Available at: http://www.reuters.com/
article/2012/10/25/idUS119103+25-Oct-2012+BW20121025
(accessed date: 6th March 2014)].
15] Cardiology Today. DESolve Nx: 6-month results strong for biore-
sorbable scaffold; 2013 [Available at: http://www.healio.com/
cardiology/intervention/news/print/cardiology-today/%7
Bfa656e62-9806-451a-9f1c-cfda23e71827%7D/desolve-nx-6-
month-results-strong-for-bioresorbable-scaffold (accessed
date: 6th March 2014)].
16] Business Wire. Arterial Remodeling Technologies (‘ART’)
reports 30-day results for the ‘ARTDIVA’ clinical trial of its next-
generation bioresorbable stent at ‘TCT 2013’ annual scientiﬁc
meeting; 2013 [Available at: http://www.businesswire.com/
news/home/20131028005236/en/Arterial-Remodeling-
Technologies-%E2%80%98ART%E2%80%99-reports-30-day-
results#.Uv4h K1HfTM (accessed date: 14th February 2014)].
17] Haude M, Erbel R, Erne P, et al. Safety and performance
of the drug-eluting absorbable metal scaffold (DREAMS) in
patients with de-novo coronary lesions: 12-month results of the
prospective, multicentre, ﬁrst-in-man BIOSOLVE-I trial. Lancet
2013;381:836—44.
18] Waksman R, Erbel R, Di Mario C, et al. Early- and long-term
intravascular ultrasound and angiographic ﬁndings after bioab-
sorbable magnesium stent implantation in human coronary
arteries. JACC Cardiovasc Interv 2009;2:312—20.
 [
[
[
[
[
[
[
[
[Fully  bioresorbable  drug-eluting  coronary  scaffolds:  A  review
[19] Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable
everolimus-eluting coronary stent system (ABSORB): 2-year
outcomes and results from multiple imaging methods. Lancet
2009;373:897—910.
[20] Diletti R, Farooq V, Girasis C, et al. Clinical and intravascular
imaging outcomes at 1 and 2 years after implantation of absorb
everolimus eluting bioresorbable vascular scaffolds in small
vessels. Late lumen enlargement: does bioresorption matter
with small vessel size? Insight from the ABSORB cohort B trial.
Heart 2013;99:98—105.
[21] Diletti R, Onuma Y, Farooq V, et al. 6-month clinical outcomes
following implantation of the bioresorbable everolimus-eluting
vascular scaffold in vessels smaller or larger than 2.5 mm. J Am
Coll Cardiol 2011;58:258—64.
[22] Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the sec-
ond generation of a bioresorbable everolimus-eluting vascular
scaffold for the treatment of de novo coronary artery steno-
sis: 12-month clinical and imaging outcomes. J Am Coll Cardiol
2011;58:1578—88.
[23] Simsek C, Magro M, Onuma Y, et al. Procedural and clinical out-
comes of the absorb everolimus-eluting bioresorbable vascular
scaffold: one-month results of the bioresorbable vascular scaf-
fold evaluated at Rotterdam Cardiology Hospitals (B-SEARCH).
EuroIntervention 2014;10:236—40.
[24] Ishibashi Y, Onuma Y, Muramatsu T, et al. Lessons learned from
acute and late scaffold failures in the ABSORB EXTEND trial.
EuroIntervention 2014;10:449—57.
[25] Muramatsu T, Onuma Y, Garcia-Garcia HM, et al. Incidence
and short-term clinical outcomes of small side branch occlu-
sion after implantation of an everolimus-eluting bioresorbable
vascular scaffold: an interim report of 435 patients in
the ABSORB-EXTEND single-arm trial in comparison with an
everolimus-eluting metallic stent in the SPIRIT ﬁrst and II trials.
JACC Cardiovasc Interv 2013;6:247—57.
[26] Abizaid A, Costa Jr JR, Bartorelli AL, et al. The ABSORB
EXTEND study: preliminary report of the twelve-month clinical
outcomes in the ﬁrst 512 patients enrolled. EuroIntervention
2014;10:1396—401.
[27] Kocka V, Maly M, Tousek P, et al. Bioresorbable vascular
scaffolds in acute ST-segment elevation myocardial infarc-
tion: a prospective multicentre study ‘Prague 19’. Eur Heart
J 2014;35:787—94.
[28] Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting
bioresorbable vascular scaffolds for treatment of patients pre-
senting with ST-segment elevation myocardial infarction: BVS
STEMI ﬁrst study. Eur Heart J 2014;35:777—86.[29] Diletti R, Serruys PW, Farooq V, et al. ABSORB II randomized
controlled trial: a clinical evaluation to compare the safety,
efﬁcacy, and performance of the absorb everolimus-eluting
bioresorbable vascular scaffold system against the XIENCE397
everolimus-eluting coronary stent system in the treatment of
subjects with ischemic heart disease caused by de novo native
coronary artery lesions: rationale and study design. Am Heart
J 2012;164:654—63.
30] Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable
everolimus-eluting scaffold versus a metallic everolimus-
eluting stent for ischaemic heart disease caused by de-novo
native coronary artery lesions (ABSORB II): an interim 1-year
analysis of clinical and procedural secondary outcomes from a
randomised controlled trial. Lancet 2015;385:43—54.
31] Woudstra P, Grundeken MJ, Kraak RP, et al. Amsterdam
investigator-initiated absorb strategy all-comers trial (AIDA
trial): a clinical evaluation comparing the efﬁcacy and per-
formance of ABSORB everolimus-eluting bioresorbable vascular
scaffold strategy vs the XIENCE family (XIENCE PRIME or
XIENCE Xpedition) everolimus-eluting coronary stent strategy
in the treatment of coronary lesions in consecutive all-
comers: rationale and study design. Am Heart J 2014;167:
133—40.
32] ClinicalTrials.gov. A service of the U.S. National Institutes of
Health [Available at: http://www.clinicaltrials.gov/ct2/home
(accessed date: 8th March 2014)].
33] Verheye S, Ormiston JA, Stewart J, et al. A next-generation
bioresorbable coronary scaffold system: from bench to ﬁrst
clinical evaluation: 6- and 12-month clinical and multimodality
imaging results. JACC Cardiovasc Interv 2014;7:89—99.
34] Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable
everolimus-eluting coronary stent system for patients with sin-
gle de-novo coronary artery lesions (ABSORB): a prospective
open-label trial. Lancet 2008;371:899—907.
35] Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results
of clinical follow-up after a bioresorbable everolimus-eluting
scaffold in patients with de novo coronary artery disease: the
ABSORB trial. EuroIntervention 2010;6:447—53.
36] Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert
K, Serruys PW. Four-year clinical follow-up of the ABSORB
everolimus-eluting bioresorbable vascular scaffold in patients
with de novo coronary artery disease: the ABSORB trial. EuroIn-
tervention 2012;7:1060—1.
37] Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and func-
tional multislice computed tomography angiographic results
after coronary implantation of the fully resorbable polymeric
everolimus-eluting scaffold in patients with de novo coronary
artery disease: the ABSORB cohort A trial. JACC Cardiovasc
Interv 2013;6:999—1009.
38] Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the
second generation of a bioresorbable everolimus drug-eluting
vascular scaffold for treatment of de novo coronary artery
stenosis: six-month clinical and imaging outcomes. Circulation
2010;122:2301—12.
